- Events & ActivityEvents & Activity
- Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
- Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
- Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium(TM) 2017
- Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium(TM) 2017
- Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A
- Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
As of last trade
Abeona Therapeutics Inc (ABEO:NAQ) traded at 5.95, -36.97% below its 52-week high of 9.44, set on Oct 20, 2016.
2.31Jul 14 20169.44Oct 20 2016
Markit short selling activity
|Market cap||247.57m USD|
|EPS (TTM)||-0.5983 USD|
Data delayed at least 15 minutes, as of May 22 2017 18:14 BST.